Skip to main content
. Author manuscript; available in PMC: 2010 Apr 15.
Published in final edited form as: Clin Cancer Res. 2008 Dec 10;14(24):8263–8269. doi: 10.1158/1078-0432.CCR-08-0480

Table 1.

Baseline characteristics according to plasma IGF-I and IGFBP-3 (N = 527)

IGF-I (quartiles)
IGFBP-3 (quartiles)
1 2 3 4 1 2 3 4
Median age, y 64 60 61 58 63 63 58 59
Median BMI, kg/m2 25.3 25.4 26.5 27.1 25.5 26.5 25.9 27.1
Male (%) 39 50 70 76 63 56 66 49
ECOG PS = 2 (%) 11 2 3 2 7 7 2 2
Treatment arm (%)
 IFL 22 25 23 19 27 20 18 23
 FOLFOX4 52 56 60 63 52 62 61 57
 IROX 26 19 17 18 21 18 21 20
Race (%)
 White 89 86 86 83 89 84 84 87
 Non-white 11 14 14 17 11 16 16 13

Abbreviations: kg/m2, kilograms per meters squared; ECOG PS, Eastern Cooperative Oncology Group performance status; IFL, bolus irinotecan, 5-FU, and leucovorin; FOLFOX4, infusional 5-FU, leucovorin, and oxaliplatin; IROX, irinotecan and oxaliplatin.

HHS Vulnerability Disclosure